Yayıncı "Future Medicine Ltd." PubMed İndeksli Yayınlar Koleksiyonu için listeleme
Toplam kayıt 1, listelenen: 1-1
-
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study
(Future Medicine Ltd., 2022)Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell ...